 Wall Street Journal [1] |
Bristol Puts Focus on Diabetes Treatment [1]
Wall Street Journal Bristol-Myers Squibb hopes to accelerate sales of diabetes drug Bydureon, which Bristol stands to obtain with its proposed purchase of Amylin. Diabetes Treatment: Bristol-Myers Buys Amylin Pharmaceuticals [2]WebProNews TEXT-Fitch cuts Bristol-Myers Squibb ratings [3]Reuters Ahead of the Bell: Amylin Pharma shares climb [4]Businessweek Worcester Telegram [5] all 443 news articles » [6] |
More details can be found at www.diabeteshowto.com [7]